Published in Vaccine Weekly, December 25th, 2002
"The intent was to enhance antigen presentation by increasing interactions between the tumor cell lines in the vaccine and GM-CSF receptor positive antigen presenting cells, notably the patient's Langerhans cells residing within the intradermal injection site," explained S. Yei and colleagues at Immune Response Corporation in Carlsbad, California.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.